Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise for rare, severe psoriasis

NCT ID NCT05352893

Disease control Sponsor: Vanda Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This Phase 3 trial tested a drug called imsidolimab in 45 adults with generalized pustular psoriasis (GPP), a rare and severe skin condition that causes painful pustules. Participants received either a single intravenous dose of imsidolimab (750 mg or 300 mg) or a placebo. The main goal was to see if the drug could clear or nearly clear the pustules and skin redness within a week. The study is now complete, and results will show whether imsidolimab can help control GPP flare-ups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
imsidolimab (ANB019)
What this could lead to
If it works, this could offer a new treatment option for people with generalized pustular psoriasis, helping to clear painful pustules and control flare-ups.
What could go wrong
This is a relatively small Phase 3 trial (45 people), so results may not apply to everyone. As with any drug, there may be side effects, and the placebo group helps measure true benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

45 people

The number who actually took part.

Started

Apr 2022

Finished

Aug 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- Subject has a BSA affected with pustules (excluding palms and soles) ≥ 5%, a GPPPGA score ≥ 3 (moderate severity), and a PRS score ≥ 3 (moderate severity) at Day 1 Exclusion Criteria: * Subject has other form of psoriasis excluding psoriasis vulgaris * Subject flare is so severe that patient's life is at risk

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Generalized pustular psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

generalized pustular psoriasis psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Generalized pustular psoriasis

Contacts and locations

Locations

  • Sie 24-105

    Valencia, 46026, Spain

  • Site 10-101

    Ann Arbor, Michigan, 48109, United States

  • Site 10-102

    Springville, Utah, 84663, United States

  • Site 10-105

    Louisville, Kentucky, 40217, United States

  • Site 10-108

    Dallas, Texas, 75231, United States

  • Site 10-109

    Largo, Florida, 33770, United States

  • Site 16-101

    Paris, 75010, France

  • Site 16-102

    Nantes, 44093, France

  • Site 17-102

    Bensheim, 48455, Germany

  • Site 17-103

    Hanau, 63450, Germany

  • Site 17-104

    Bonn, 53127, Germany

  • Site 17-105

    Würzburg, 97080, Germany

  • Site 24-101

    Barcelona, 08036, Spain

  • Site 24-102

    Madrid, 28040, Spain

  • Site 24-103

    Madrid, 28041, Spain

  • Site 24-104

    Las Palmas de Gran Canaria, 35010, Spain

  • Site 30-101

    Rzeszów, 35-055, Poland

  • Site 30-102

    Wroclaw, 50-566, Poland

  • Site 30-103

    Ossy, 42-624, Poland

  • Site 30-104

    Krakow, 30-074, Poland

  • Site 30-105

    Lodz, 90-265, Poland

  • Site 31-101

    Cluj-Napoca, 400006, Romania

  • Site 31-102

    Bucharest, 020125, Romania

  • Site 31-103

    Iași, 700111, Romania

  • Site 33-101

    Kayseri, 38039, Turkey (Türkiye)

  • Site 33-102

    Ankara, 06560, Turkey (Türkiye)

  • Site 33-103

    Bursa, 16059, Turkey (Türkiye)

  • Site 33-104

    Antalya, 07070, Turkey (Türkiye)

  • Site 33-105

    Istanbul, 24093, Turkey (Türkiye)

  • Site 33-106

    Istanbul, 34010, Turkey (Türkiye)

  • Site 35-102

    Melbourne, Victoria, 3128, Australia

  • Site 42-101

    Kuala Lumpur, 50586, Malaysia

  • Site 42-102

    Muar town, Johor, 84000, Malaysia

  • Site 42-103

    Putrajaya, 62250, Malaysia

  • Site 42-104

    Kuala Lumpur, 56000, Malaysia

  • Site 42-105

    Kota Bharu, Kelantan, 15586, Malaysia

  • Site 42-106

    Johor Bahru, Johor, 80100, Malaysia

  • Site 42-107

    Johor Bahru, Johor, 81100, Malaysia

  • Site 42-108

    Kuching, Sarawak, 93586, Malaysia

  • Site 42-109

    Batu Caves, Selangor, 59100, Malaysia

  • Site 42-110

    Kuala Lumpur, 59100, Malaysia

  • Site 45-101

    Seoul, 05505, South Korea

  • Site 45-102

    Busan, 49241, South Korea

  • Site 45-103

    Seoul, 06591, South Korea

  • Site 45-104

    Seoul, 03722, South Korea

  • Site 46-101

    Bangkok, 10400, Thailand

  • Site 46-102

    Chiang Mai, 50200, Thailand

  • Site 46-103

    Pathum Thani, 12120, Thailand

  • Site 46-104

    Khon Kaen, 40002, Thailand

  • Site 59-101

    Tbilisi, 0160, Georgia

  • Site 59-102

    Tbilisi, 0112, Georgia

  • Site 59-103

    Tbilisi, 0179, Georgia

  • Site 59-104

    Batumi, 6000, Georgia

  • Site 59-105

    Tbilisi, 0160, Georgia

  • Site 62-101

    Sfax, 3000, Tunisia

  • Site 62-102

    Sousse, 4000, Tunisia

  • Site 62-103

    Tunis, 1007, Tunisia

  • Site 63-101

    Kaohsiung City, 83301, Taiwan

  • Site 63-102

    Taipei, 11696, Taiwan

  • Site 63-103

    New Taipei City, 23561, Taiwan

  • Site 63-104

    Taipei, 11217, Taiwan

  • Site 63-105

    Taipei, 100225, Taiwan

  • Site 64-101

    Marrakesh, 40000, Morocco

  • Site 64-102

    Oujda, 60000, Morocco

  • Site 64-103

    Casablanca, 20360, Morocco

More trials for these conditions

Other studies related to the condition(s) this trial covers.